Find a Physician | How to Contribute | About Us | Clinical Trials
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG VRXP-A202

A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Principal Investigator
Mark Agulnik
  • Status: COMPLETED
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG VRXP-A202
The goal of this research study is to compare the standard treatment to the standard treatment plus VTX-2337 to see if it helps cancer tumors stop growing or shrink, and if it helps patients with squamous cell carcinoma of the head and neck (SCCHN) live longer. Researchers also want to determine the side effects of the experimental combination of standard treatment and VTX-2337.
A standard treatment regimen for SCCHN consists of a combination of carboplatin or cisplatin, 5 fluorouracil [5-FU], and cetuximab. This standard treatment is approved by the US Food and Drug Administration (FDA) for treatment of SCCHN. This research study involves adding either VTX-2337 or placebo (an injection that does not contain active drug) to the standard treatment described above. VTX-2337 is an investigational drug that activates multiple components of the body’s immune system (protects the body against disease). An investigational drug is one that is not yet approved by the FDA.
Some of the eligibility criteria include:
  • Participants must have squamous cell carcinoma of the head and neck that is recurrent (came back after prior treatment) or metastatic (has spread beyond the head and neck).
  • Participants must be 18 years of age or older.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
The treatment period is split into two phases: initial treatment and subsequent treatment. The initial treatment includes six 21-day cycles where participants will receive cisplatin or carboplatin, 5-FU, cetuximab, and study drug/placebo. Starting with Cycle 7, treatment with cisplatin/carboplatin and 5-FU will be discontinued and participants will continue to receive study drug/placebo and cetuximab. Cycles 7 onwards are 28-day cycles instead of 21-day cycles. Participants will continue to receive cetuximab and study drug/placebo until their disease gets worse or they can no longer tolerate the treatment (experience any unacceptable side effects).
Clinical Trials Recruitment Nurse
Robert H. Lurie Comprehensive Cancer Center

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Mark Agulnik

last updated: 26-Sep-17 09:28 AM


Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.